Denosumab-induced severe hypocalcemia in a patient with Crohn's disease
Metadata[+] Show full item record
Osteoporosis occurs with increased prevalence in individuals with inflammatory bowel disease (IBD), and as such, these patients are at risk for osteoporosis-related fractures. Although bisphosphonates remain the most commonly used class of drugs for managing osteoporosis, the effectiveness of oral bisphosphonates in patients with IBD may be diminished due to distressing gastrointestinal side effects, which hinder compliance, and also due to poor absorption by diseased intestine.
M C Spiegel, T Tidwell, R Mulyala, N Katta, Denosumab-Induced Severe Hypocalcemia in a Patient with Crohn's Disease. Journal of Academic Hospital Medicine 2014, Volume 6, Issue 4.